A federal judge has put on hold the lawsuit that posed the broadest threat to nationwide access to the abortion pill, pausing the case until December 1 or until the Food and Drug Administration completes its ongoing safety study of mifepristone, whichever comes first.
U.S. District Judge Reed O'Connor of the Northern District of Texas granted a Justice Department request to pause the suit brought by the attorneys general of Texas and Florida, which asks the court to unwind the FDA's 2000 approval of the drug entirely. Both states agreed to the delay. In the same order, O'Connor denied a motion to dismiss the case filed by generic manufacturer GenBioPro and distributor Danco Laboratories, which intervened as defendants earlier this year.
For patients, clinicians and pharmacists, nothing changes today. Mifepristone remains approved, prescriptions remain valid, and the current dispensing rules stay in force. What the pause does is push the decisive moment onto the FDA rather than the court, and set a date by which the picture is likely to look different.
A Pause That Leaves Current Access Unchanged
The distinction between a pause and a ruling matters here, because it is easy to read a court delay as a change in the law. It is not one. No injunction was issued, no approval was suspended, and no prescribing rule was altered.
Under the current framework, mifepristone is approved for ending a pregnancy through 70 days of gestation, taken with a second drug, misoprostol. The FDA formally removed the in person dispensing requirement when it modified the risk evaluation and mitigation strategy in January 2023, so patients can obtain the drug through telehealth, by mail and at certified pharmacies. Those rules are unaffected by the order.
Medication abortion is not a niche route. A Guttmacher Institute analysis cited in a KFF overview of the availability and use of medication abortion found it accounted for 63 percent of all nonhospital abortions in 2023. Separate tracking by the Society of Family Planning found that 27 percent of all abortions in the first half of 2025 were provided through telehealth. The same drug is also used in miscarriage management, a use that receives far less attention in litigation coverage.
Households Most Exposed to the Uncertainty
The people carrying the most practical uncertainty are not evenly distributed. Patients in states without local providers who rely on mailed prescriptions face the sharpest exposure, because the mail and telehealth pathway is the specific target of a separate case still moving through the courts.
Rural households sit in a similar position. When the nearest certified prescriber is hours away, a return to in person dispensing requirements would convert a single telehealth appointment into travel, time off work and child care arrangements. Cost follows access. Patients who lose a mail based option often face higher total out of pocket spending even when the medication price itself does not move.
Clinicians managing early pregnancy loss are a group frequently left out of this conversation entirely. They prescribe the same drug for a different purpose, and regulatory changes aimed at abortion would reach them too.
For anyone currently planning care, the reasonable step is to confirm details with a licensed clinician or pharmacy rather than acting on litigation headlines, and to avoid ordering medications from unverified online sellers.
The Review Driving the Court's Timeline
On its public question and answer page, the FDA said that as of April 2026 it was still working to collect the data necessary for a well-controlled study with adequate statistical power, with subsequent steps covering data exploration, integrity checks, analysis, validation and peer review. The agency said it would then decide whether substantive changes to the risk evaluation and mitigation strategy are warranted.
The FDA has not published a completion date. It noted that academic studies of this kind often take about a year or more, and said its current plan is to finish sooner than that without cutting scientific corners.
Major medical organizations dispute the premise that the safety record is unsettled. The American College of Obstetricians and Gynecologists led a coalition of 15 organizations in an amicus brief supporting current dispensing rules, arguing that decades of evidence and clinical practice show the drug is safe and effective whether dispensed in person or by mail.
"ACOG supports the safety and efficacy of this medication" as part of evidence-based care, said Steven J. Fleischman, MD, president of the organization, in its statement announcing the filing.
Regulators have not endorsed that framing while their review is open, and the agency has not stated a preliminary conclusion.
Other Cases Still Moving Forward
The pause covers one case, not the field. On September 9, the U.S. Court of Appeals for the Fifth Circuit is scheduled to hear arguments in the Louisiana challenge to the FDA regulation permitting mifepristone to be prescribed through telehealth, dispensed in pharmacies and delivered by mail. That is the case most directly tied to how patients obtain the drug. In May, the Supreme Court blocked a lower court order in that case, leaving current rules in place while the litigation continues.
A separate suit brought by Missouri, Kansas and Idaho seeks to restore requirements that were in place before 2016, when the drug was approved only through seven weeks of gestation, required three in-person visits and had no generic version.
Several things remain genuinely unknown. The FDA has not said when its study will conclude or what it will recommend. The court has not indicated what happens if the work runs past December 1. And no ruling has been issued on the merits of any of the claims, which means allegations in these filings should not be read as findings.
Readers should watch for the Fifth Circuit argument, any FDA announcement on the safety study, and the December 1 date on the paused case. MedicalDaily will report each development as it is confirmed.
Key Questions Answered
What did the judge decide? Judge Reed O'Connor paused the Texas and Florida lawsuit until December 1 or until the FDA finishes its mifepristone safety study, whichever happens first.
Does this change access to the drug right now? No. Mifepristone remains approved, and current prescribing and dispensing rules are unchanged.
What were the states asking for? The two attorneys general asked the court to roll back the FDA's 2000 approval of mifepristone entirely.
Did both sides agree to the delay? Yes. The Department of Justice requested the pause, and both Texas and Florida agreed to it.
What is the FDA reviewing? The agency is conducting a retrospective safety study and will then decide whether to change the drug's risk evaluation and mitigation strategy.
Is any other case still active? Yes. The Fifth Circuit hears the Louisiana telehealth and mail order challenge on September 9, and a separate suit from Missouri, Kansas and Idaho seeks pre 2016 restrictions.
What should patients do now? Confirm current options with a licensed clinician or pharmacy, and avoid purchasing medications from unverified online sellers.
